A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants

The candidate malaria vaccine RTS,S/AS01 reduced episodes of both clinical and severe malaria in children 5 to 17 months of age by approximately 50% in an ongoing phase 3 trial. The researchers studied infants 6 to 12 weeks of age recruited for the same trial.The study concludes that the RTS,S/AS01 vaccine coadministered with EPI vaccines provided modest protection against both clinical and severe malaria in young infants.